

APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)


HE 20.4210 : 105 / suppl. 7

The University
of Michigan
Pharmacy
Library

477-K-5


Pharm.
RM
300
1053

4th ed.
Suppl. 9



**CUMULATIVE
SUPPLEMENT 9
AUG'83 - MAY'84**

SERIAL



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

REFERENCE
DO NOT REMOVE

UNIVERSITY OF MICHIGAN
LIBRARIES

JUL 26 1984

DEPOSITED BY THE
UNITED STATES OF AMERICA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUGS AND BIOLOGICS

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

Digitized by **Google**

Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition (the List), to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature, are identified by the term "List". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol > ADD > to the left of the line on which new information exists. The > ADD > symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT (DELETE) to the left of the line containing the overstruck print. The >DLT symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (★) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS CONTAINING PHENACETIN

The October 5, 1983, Federal Register (48FR45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983.

Because the subject products are no longer approved, the cumulative supplement has identified them by deleting the applicable active ingredient headers followed by a reference to this Special Note.

C. THEOPHYLLINE CONTROLLED RELEASE

Two controlled released theophylline tablets are listed as therapeutically equivalent (AB). Because one of these products was recently approved for once-daily dosing, it is important to be aware that the therapeutic equivalence rating was made on the basis of 12-hour dosing intervals. The rating does not apply to once-daily dosing. To date, no data have been submitted upon which the Agency can base a therapeutic equivalence determination among any of the approved theophylline controlled-release products when dosed once-daily.

D. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

<u>Former Applicant (Name)</u>	<u>New Applicant (Name)</u>	<u>New Abbreviated Name</u>
STERI-MED INC SUB KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
PROFESSIONAL PHARMACAL DIV STERI-MED INC	OPTOPICS LABORATORIES	OPTOPICS LABS
MPL INC SOLOPAK DIV	SOLOPAK LABORATORIES	SOLOPAK LABORATORIES

The reader should consult the above cumulative list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 4th Edition of the ADP, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and marketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the List composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

<u>CATEGORIES COUNTED</u>	<u>JULY '83 (BASELINE)</u>	<u>OCT '83</u>	<u>JAN '84</u>	<u>APR '84</u>
DRUG PRODUCTS LISTED	6679	6783	6854	6938
SINGLE SOURCE	1908 (28.6%)	1915 (28.2%)	1933 (28.2%)	1940 (28.0%)
MULTISOURCE (1)	4771 (71.4%)	4868 (71.8%)	4921 (71.8%)	4998 (72.0%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)	3891 (57.4%)	3939 (57.5%)	4014 (57.9%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)	967 (14.3%)	972 (14.2%)	974 (14.0%)
EXCEPTIONS (2)	10 (0.1%)	10 (0.1%)	10 (0.1%)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	2	8	9
NUMBER OF APPLICANTS	304	310	312	313

B. ACTIVITY FOR SUPPLEMENT NUMBER 9

	<u>MAY '84</u>	<u>CUMULATIVE</u>
DRUG PRODUCTS ADDED:	52	52
NEWLY APPROVED	52	52
DESI EFFECTIVE	0	0
REMARKETED	0	0
DRUG PRODUCTS REMOVED:	14	14
WITHDRAWN APPROVAL	0	0
RX TO OTC SWITCH	0	0
DISCONTINUED MARKETING	14	14
NET GAIN IN DRUG PRODUCTS	38	38
SINGLE SOURCE PRODUCTS APPROVED	18	18
MULTISOURCE DRUG PRODUCTS APPROVED	34	34
NEW MOLECULAR ENTITIES APPROVED:	5	5
AS THE ENTITY-	3	3
AS A SALT, ESTER OR DERIVATIVE		
OF THE ENTITY	2	2

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.E., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 1-5 OF THE LIST)

v

Digitized by **Google**

Original from
UNIVERSITY OF MICHIGAN

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL		
<u>ACETAMINOPHEN W/ CODEINE #3</u>		
AA	LEHMON	300MG;30MG
<u>TYLENOL W/ CODEINE NO. 3</u>		
AA	MCNEIL PHARM	300MG;30MG
TABLET; ORAL		
<u>ACETAMINOPHEN AND CODEINE PHOSPHATE</u>		
AA	DURAMED PHARMS	300MG;15MG
AA		300MG;30MG
AA		300MG;60MG
<u>PAPA-DEINE #3</u>		
AA	VANGARD LABS/WM	300MG;30MG
<u>PAPA-DEINE #4</u>		
AA	VANGARD LABS/WM	300MG;60MG

ACETAMINOPHEN; HYDROCODONE BITARTRATE (PAGE 3-2)

TABLET; ORAL		
<u>HYCODAPHEN</u>		
AA	BF ASCHER	300MG;8MG

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL		
<u>CODACET</u>		
AA	HALSEY DRUG	325MG;8MG
<u>PERCOCET-B/</u>		
<u>PERCOCET</u>		

/ACETAMINOPHEN; PHENACETIN; PHENYLPROPANOLAMINE HYDROCHLORIDE;/
PHENYLTOLOXAMINE CITRATE/(PAGE 3-2)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ALBUMIN, IODINATED, I-131, SERUM (PAGE 3-4)

INJECTABLE; INJECTION
/RADIOIODINATED SERUM ALBUMIN (HUMAN) I-131/
/MALLINCKRODT/ 16.7:550, 16.7:100/

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION		
<u>AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTIDINE</u>		
	CUTTER-VITRUM	5.2%
<u>AMINOSYN 3.5% IN PLASTIC CONTAINER</u>		
	ABBOTT LABORATORIES	3.5%
<u>NEOPHAM 6.5%</u>		
	CUTTER-VITRUM	6.5%

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM
ACETATE; SODIUM CHLORIDE (PAGE 3-7)

INJECTABLE; INJECTION		
<u>AMINOSYN 3.5% M IN PLASTIC CONTAINER</u>		
	ABBOTT LABORATORIES	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML; 234MG/100ML

AMINOPHYLLINE (PAGE 3-8)

<u>/Liquid, Oral/</u>		
<u>SOLUTION; ORAL</u>		
<u>AMINOPHYLLINE</u>		
AA	BAY LABORATORIES	105MG/5ML
AA	ROXANE LABORATORIES	105MG/5ML

TABLET; ORAL		
<u>AMINOPHYLLINE</u>		
BD	BARR LABORATORIES	100MG
BD		200MG
AB	VANGARD LABS/WM	100MG
AB		200MG

AMITRIPTYLINE HYDROCHLORIDE (PAGE 3-9)

TABLET; ORAL		
<u>AMITRIPTYLINE HCL</u>		
AB	DANBURY PHARMACAL	10MG
AB		25MG
AB		50MG
AB		75MG
AB		100MG
AB		150MG
BP	COLEY PHARM	10MG
BP		25MG
BP		50MG
BP		75MG
BP		100MG
BP		150MG

ASPIRIN: BUTALBUTAL: CAFEINE: (PAGE 3-15)
CAPSULE: ORAL
SYNLABS-DC
IVES LABS/AMHO
356.4MG;30MG;16MG

ASPIRIN: BUTALBUTAL: CAFEINE: (PAGE 3-15)
(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN: BUTALBUTAL: CAFEINE: (PAGE 3-15)
TABLET: ORAL
ASPIRIN AND CAFEINE W/ BUTALBUTAL
PUREPAC/KALIPHARM 325MG;50MG;40MG
BUTAL COMPOUND
CORD LABORATORIES 325MG;50MG;40MG
BUTALBUTAL W/ ASPIRIN AND CAFEINE
CHELSEA LABORATORIES 325MG;50MG;40MG
BUTALBUTAL W/ ASPIRIN & CAFEINE
BOOTS LABORATORIES 325MG;50MG;40MG

ASPIRIN: BUTALBUTAL: CAFEINE: (PAGE 3-15)

TABLET: ORAL
AXOTAL
ADRIA LABORATORIES 650MG;50MG

ASPIRIN: BUTALBUTAL: (PAGE 3-15)

ASPIRIN: BUTALBUTAL: (PAGE 3-15)
POWDER FOR RECONSTITUTION: ORAL
POLYGLIN-200
BRISTOL LABS/B-M
EQ 3.5GM BASE/BOT:15M/BOT
PROBAPACIN
BIOCRRAFT LABS
EQ 3.5GM BASE/BOT:15M/BOT

AMPICILLIN TRIMOPRIM: PROBENECID (PAGE 3-13)

ASPIRIN: BUTALBUTAL: CAFEINE: (PAGE 3-13)
CAPSULE: CONTAINED RELEASE: ORAL
BENZODOLINE
SKAF LABORATORIES/ 15MG/
TABLET: ORAL
BENZODOLINE
SKAF LABORATORIES/ 5MG/
SKAF LABORATORIES/ 10MG/

ASPIRIN: BUTALBUTAL: CAFEINE: (PAGE 3-13)

ASPIRIN: BUTALBUTAL: CAFEINE: (PAGE 3-17)
LIQUID: ORAL
/ 100MG/5MG/5MG/
/ 5.425MG/5MG/5MG/
/ 5.425MG/5MG/5MG/
/ 5.425MG/5MG/5MG/

ATROPINE SULFATE: DIPHENOXYLATE HYDROCHLORIDE (PAGE 3-17)

INJECTABLE: INJECTION
TRACRIUM
BURNBOUGHS WELLCOME 10MG/MLM

ATROPINE SULFATE: DIPHENOXYLATE (PAGE 3-16)

TABLET: ORAL
VICOPRIN
KNOLL PHARMACEUTICAL 500MG;5MG

ASPIRIN: HYDROCODONE BITARTRATE (PAGE 3-16)

TABLET: ORAL
SOMA COMPOUND W/ CODEINE
MALLACE PHARMS/C-M 325MG;200MG;16MG

ASPIRIN: CARISOPRODOL: CODEINE PHOSPHATE (PAGE 3-16)

TABLET: ORAL
SOMA COMPOUND
MALLACE PHARMS/C-M 325MG;200MG

ASPIRIN: CARISOPRODOL: (PAGE 3-16)

ASPIRIN: CARISOPRODOL: (PAGE 3-16)
CAPSULE: ORAL
BARVON COMPOUND-65
ELI LILLY INDSTRS/PR 325MG;32.4MG;65MG
PROPOXYPHENE COMPOUND 65
LEMON
325MG;32.4MG;65MG
SK-65 COMPOUND
SKAF LABORATORIES 325MG;32.4MG;65MG

ASPIRIN: CAFEINE: PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN: CAFEINE: PROPOXYPHENE HYDROCHLORIDE (PAGE 3-15)
(PAGE 3-15)

AMPHETAMINE (PAGE 3-18)

BRAND: ORAL
DIAGNEX BLUE
ER. SCOTT & BOWNE / 250MG/PACKET/

BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)

TABLET; ORAL
SPECTROBID
PFIZER LABS/PFIZER 800MG

BACITRACIN (PAGE 3-18)

OINTMENT; OPHTHALMIC
BACITRACIN
AT PHARMAFAIR 500 UNITS/GM

BENTITROMIDE (PAGE 3-19)

SOLUTION; ORAL
CHYMEX
ADRIA LABORATORIES 500MG/7.5ML

BENZTHIAZIDE (PAGE 3-20)

TABLET; ORAL
AQUATAG
/BP/ /CORP. LABORATORIES/ /50MG/
/25MG/
BP REID-PROVIDENT LABS 50MG
25MG
/PROLOG/

BENZTROPINE MESYLATE (PAGE 3-20)

TABLET; ORAL
BENZTROPINE MESYLATE
BP QUANTUM PHARMICS 0.5MG
BP 1MG
BP 2MG
COGENTIN
BP MSD/MERCK 0.5MG
BP 1MG
BP 2MG

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL

BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE

LOTION; TOPICAL

BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE
VALISONE
AB SCHERING EQ 0.1% BASE

OINTMENT; TOPICAL

BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE
VALISONE
AB SCHERING EQ 0.1% BASE

BETHANECHOL CHLORIDE (PAGE 3-21)

TABLET; ORAL

BETHANECHOL CHLORIDE
> ADD > AA SIDMAK LABORATORIES 10MG
> ADD > AA 25MG

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
(PAGE 3-22)

SYRUP; ORAL

AMBENYL
MARION LABORATORIES 12.5MG/5ML; 10MG/5ML

BROMPHENIRAMINE MALEATE (PAGE 3-22)

TABLET; ORAL

BROMPHENIRAMINE MALEATE
/AA/ /BOLAR PHARMACEUTICAL/ 4MG

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE;
PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-23)

SYRUP; ORAL

DINETANE-DC
AM ROBINS 2MG/5ML; 10MG/5ML; 12.5MG/5ML

Original from
UNIVERSITY OF MICHIGAN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;
SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE (PAGE 3-27)

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
AM MCGAW/AM HOSP 35MG/100ML;30MG/100ML;
74MG/100ML;640MG/100ML;
500MG/100ML;74MG/100ML

> ADD > CEFONICID SODIUM (PAGE 3-30)

> ADD > INJECTABLE; INJECTION
> ADD > MONOCID
> ADD > SK&F LABORATORIES EQ 500MG BASE/VIALM
> ADD > EQ 1GM BASE/VIALM
> ADD > EQ 2GM BASE/VIALM
> ADD > EQ 10GM BASE/VIALM

> ADD > CEFORANIDE (PAGE 3-30)

> ADD > INJECTABLE; INJECTION
> ADD > PRECEF
> ADD > BRISTOL LABS/B-M 500MG/VIALM
> ADD > 1GM/VIALM
> ADD > 2GM/VIALM
> ADD > 10GM/VIALM
> ADD > 20GM/VIALM

CEFTIZOXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
CEFIZOX
SK&F LABORATORIES EQ 1GM BASE/VIALM
EQ 2GM BASE/VIALM

CEFUROXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
ZINACEF
GLAXO EQ 750MG BASE/VIALM
EQ 1.5GM BASE/VIALM

CELLULOSE SODIUM PHOSPHATE (PAGE 3-30)

POWDER; ORAL
CALCIBIND
MISSION PHARMACAL 2.5GM/PACKET

CEPHALOTHIN SODIUM (PAGE 3-31)

INJECTABLE; INJECTION
> ADD > CEPHALOTHIN SODIUM
> ADD > AP BRISTOL LABS/B-M EQ 1GM BASE/VIALM
> ADD > AP EQ 2GM BASE/VIALM
> ADD > AP EQ 4GM BASE/VIALM
AP KEFLIN
AP ELI LILLY EQ 1GM BASE/VIAL
AP EQ 2GM BASE/VIAL
AP EQ 4GM BASE/VIAL
AP SEFFIN
AP GLAXO EQ 1GM BASE/VIALM
AP EQ 2GM BASE/VIALM
AP EQ 10GM BASE/VIALM

CEPHALOTHIN SODIUM; DEXTROSE (PAGE 3-31)

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
TRAVENOL LABS EQ 20MG BASE/ML;50MG/MLM
EQ 40MG BASE/ML;50MG/MLM

CEPHALOTHIN SODIUM; SODIUM CHLORIDE (PAGE 3-31)

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
TRAVENOL LABS EQ 20MG BASE/ML;9MG/MLM
EQ 40MG BASE/ML;9MG/MLM

CHLORDIAZEPOXIDE (PAGE 3-33)

CAPSULE, CONTROLLED RELEASE; ORAL
LIBRELEAS
HOFFMANN-LA ROCHE 30MGX

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-33)

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
/AB/ /BOOTS PHARMACEUTICAL/ 8MG/
/AB/ /10MG/
/AB/ /25MG/

CHLOROPROCAINE HYDROCHLORIDE (PAGE 3-34)

INJECTABLE; INJECTION
NESACAIN
/PENWALT PHARM/ 112/
/22/

CORTICOTROPIN (PAGE 3-43)

INJECTABLE; INJECTION
/BC/ REPOSITORY CORTICOTROPIN/ 40 UNITS/ML/
/BC/ MYETH LABS/AMMO/ 40 UNITS/ML/
/BC/

CYANOCOBALAMIN (PAGE 3-44)

INJECTABLE; INJECTION
CYANOCOBALAMIN
AP SOLOPAK/MPL 1MG/MLX
AP DODEGANIN 1MG/MLX
AP MAURRY BIOLOGICAL 1MG/MLX
/AB/ REDISOL 10.5MG/ML/
/AB/ MSD/MERCK 10.5MG/ML/
/AB/ SYTOREX 10.5MG/ML/
/AB/ PARKE DAVIS/M-L 10.5MG/ML/
TABLET; ORAL
/DLT/ REDISOL/ 10.5MG/
/DLT/ MSD/MERCK/ 10.5MG/

CYCLOSPORINE (PAGE 3-46)

INJECTABLE; INJECTION
SANDIMUNE
SANDOZ PHARMS/SANDOZ 50MG/MLX

SOLUTION; ORAL
SANDIMUNE
SANDOZ PHARMS/SANDOZ 100MG/MLX

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-46)

TABLET; ORAL
CYPROHEPTADINE HCL
AA DURAMED PHARMS 5MGX
AA PIONEER PHARMS 4MGX

DAPSONE (PAGE 3-47)

TABLET; ORAL
/AB/ JACOBUS PHARM/ 25MG/
/BP/ INTERST. LABS/AMMO/ 100MG/
/BP/ DAPSONE 25MG
/BP/ JACOBUS PHARM 100MG
/BP/

DESMOPRESSIN ACETATE (PAGE 3-48)

INJECTABLE; INJECTION
DDAVP
ARMOUR PHARM 0.004MG/MLX

DESOXIMETASONE (PAGE 3-49)

ointment; TOPICAL
TOPICORT
HOECHST-ROUSSEL 0.252X

DEXAMETHASONE (PAGE 3-49)

SOLUTION; ORAL
DEXAMETHASONE
ROKANE LABORATORIES 0.5MG/5MLX
DEXAMETHASONE INTENSOL
ROKANE LABORATORIES 0.5MG/0.5MLX

TABLET; ORAL
DECADRON
BP MSD/MERCK 6MG
DEXAMETHASONE
/BP/ HYLAN PHARMS/ 10.5MG/
BP PAR PHARMACEUTICAL 6MGX
BP ROXANE LABORATORIES 6MGX
1MGX

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-50)

INJECTABLE; INJECTION
DEXAMETHASONE
AP INVENEX LABS/DEXTER EQ 4MG PHOSPHATE/MLX
AP EQ 10MG PHOSPHATE/MLX
AP DEXAMETHASONE SODIUM PHOSPHATE
AP INTL MEDICATION SYS EQ 20MG PHOSPHATE/MLX
/HEXADROL PHOSPHATE/
HEXADROL
AP ORGANON/AKZONA EQ 4MG PHOSPHATE/ML
AP EQ 20MG PHOSPHATE/ML

SOLUTION/DROPS; OPHTHALMIC

DEXAIR
AT PHARMAFAIR EQ 0.1% PHOSPHATEX
AT DEXAMETHASONE SODIUM PHOSPHATE
AT BARNES-HIND PHARMS EQ 0.1% PHOSPHATE

DECHLORPHENIRAMINE MALEATE (PAGE 3-51)
 SYRUP: ORAL
 BAY LABORATORIES 2MG/5ML
 POLARAZINE
 SCHERING 2MG/5ML

DEXTROMETHORPHAN HYDROBROMIDE: PROMETHAZINE HYDROCHLORIDE (PAGE 3-52)
 SYRUP: ORAL
 PHENEGAN W/ DEXTROMETHORPHAN 15MG/5ML; 6.25MG/5ML
 WELTH LABS/AMHO

DEXTROSE: DOPAMINE HYDROCHLORIDE (PAGE 3-53)
 INJECTABLE: INJECTION
 /DOPAMINE HCL IN DEXTROSE 5%
 ABBOTT LABORATORIES 5GM/100ML; 80MG/100ML
 ABBOTT LABORATORIES 5GM/100ML; 80MG/100ML
 DOPAMINE HCL IN PLASTIC CONTAINER
 ABBOTT LABORATORIES 5GM/100ML; 80MG/100ML
 ABBOTT LABORATORIES 5GM/100ML; 80MG/100ML
 DEXTROSE: HEPARIN SODIUM (PAGE 3-53)
 INJECTABLE: INJECTION
 HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
 TRAVENOL LABS 5GM/100ML; 4,000 UNITS/100ML

DEXTROSE: LIDOCAINE HYDROCHLORIDE (PAGE 3-53)
 INJECTABLE: INJECTION
 LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
 AM HCGAM/AM HOSP 5GM/100ML; 80MG/100ML
 LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
 AM HCGAM/AM HOSP 5GM/100ML; 80MG/100ML
 LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER
 AM HCGAM/AM HOSP 5GM/100ML; 80MG/100ML

DIATRIZOATE MESLUMINE: DIATRIZOATE SODIUM (PAGE 3-57)
 INJECTABLE: INJECTION
 /DIATRIZOATE MESLUMINE AND DIATRIZOATE SODIUM
 DIATRIZOATE-69

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)
 TABLET: ORAL
 DIAETYLPROPION HCL
 CARALL 25MG

DIMENHYDRINATE (PAGE 3-60)
 INJECTABLE: INJECTION
 DIMENHYDRINATE
 /44/ /100ML MEDICATION 5% / 50MG/ML

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)
 CAPSULE: ORAL
 SK-K LABORATORIES /44H/
 ELIXIR: ORAL
 DELIX
 HALSEY DRUG 12.5MG/5ML
 DIBENT
 HR CENCI LABS 12.5MG/5ML
 DIPHENHYDRAMINE HCL
 /44/ /100ML MEDICATION 5% / 50MG/ML
 /44/ /100ML MEDICATION 5% / 50MG/ML

DISULFIRAM (PAGE 3-63)
 TABLET: ORAL
 DISULFIRAM 250MG
 CHELSEA LABORATORIES 250MG
 SIDMAK LABORATORIES 250MG

DOXYCYCLINE HYCLATE (PAGE 3-64)
 CAPSULE: ORAL
 DOXYCYCLINE HYCLATE
 CHELSEA LABORATORIES 50.5MG BASE
 HEATHER DRUG 50.5MG BASE
 PAR PHARMACEUTICAL 50.5MG BASE
 PUREPAC/KALIPHARM 50.5MG BASE
 WEST-WARD 50.5MG BASE

DOXYCYCLINE HYCLATE (PAGE 3-64)

INJECTABLE; INJECTION
DOXY 100
 AP LYPHO-MED EQ 100MG BASE/VIALM
DOXY 200
 AP LYPHO-MED EQ 200MG BASE/VIALM
DOXYCYCLINE
 AP ELKINS-SINN EQ 100MG BASE/VIALM
 AP EQ 200MG BASE/VIALM
VIBRAMYCIN
 AP PFIZER LABS/PFIZER EQ 200MG BASE/VIAL

TABLET; ORAL
DOXYCYCLINE HYCLATE
 AB HEATHER DRUG EQ 100MG BASE

DROPERIDOL; FENTANYL CITRATE (PAGE 3-64)

INJECTABLE; INJECTION
 INNOVAR
 JANSSEN PHARMA 12.5MG/ML; 0.05MG/ML
 JANSSEN PHARMA 2.5MG/ML; EQ 0.05MG BASE/ML

DYCLONINE HYDROCHLORIDE (PAGE 3-64)

SOLUTION; TOPICAL
 DYCLONE
 MERRELL DOWN/DON CHEN/0.5%
 1%
 ASTRA PHARM PRODS 0.5%
 1%

ECHOTHIOPHATE IODIDE (PAGE 3-65)

POWDER FOR RECONSTITUTION; OPHTHALMIC
~~ECHOTHIOPHATE~~
 ALCON LABORATORIES 0.61%
 0.62%
 0.63%
 0.64%
 PHOSPHOLINE IODIDE
 AYERST LABS/AMHO 0.03%
 0.06%
 0.125%
 0.25%

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

INJECTABLE; INJECTION
LIDOCATON
 AP PHARMATON/SZ 0.01MG/ML; 2%
 AP 0.02MG/ML; 2%

ERGOLOID MESYLATES (PAGE 3-66)

CAPSULE; ORAL
~~HYDERGINE~~
 HYDERGINE LC
 TABLET; ORAL
ERGOLOID MESYLATES
 AB CHELSEA LABORATORIES 1MG

ERYTHROMYCIN (PAGE 3-67)

OINTMENT; OPHTHALMIC
ERYTHROMYCIN
 AT E FOUGERA/BYK-GLDN 5MG/GM
 AT PHARMADERM/BYK-GLDN 5MG/GM
 AT PHARMAFAIR 5MG/GM
 AT XLOTYCN
 AT DISTA PRODS/LILLY 5MG/GM

ESTRADIOL (PAGE 3-69)

CREAM; VAGINAL
 ESTRACE
 MEAD JOHNSON/B-M 0.01%

ESTROGENS, CONJUGATED (PAGE 3-70)

TABLET; ORAL
 PREMARIN
 AYERST LABS/AMHO 0.9MG

ETHINYL ESTRADIOL; NORETHINDRONE (PAGE 3-72)

TABLET; ORAL-21
 ORTHO-NOVUM 7/14-21
 ORTHO PHARMACEUTICAL 0.035MG; 0.5MG AND 1MG
 ORTHO-NOVUM 7/7/7-21
 ORTHO PHARMACEUTICAL 0.035MG; 0.5MG, 0.75MG AND 1MG
 TRI-NORINYL 21-DAY
 SYNTEX (FP) 0.035MG; 0.5MG AND 1MG
 TABLET; ORAL-28
 ORTHO-NOVUM 7/14-28
 ORTHO PHARMACEUTICAL 0.035MG; 0.5MG AND 1MG
 ORTHO-NOVUM 7/7/7-28
 ORTHO PHARMACEUTICAL 0.035MG; 0.5MG, 0.75MG AND 1MG
 TRI-NORINYL 28-DAY
 SYNTEX (FP) 0.035MG; 0.5MG AND 1MG

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

ITEM	DESCRIPTION	UNIT	QUANTITY	DATE	REMARKS
1	FLUCONAZOLE INJECTION	200MG/ML	10	10/10/2018	FOR INJECTION
2	FLUCONAZOLE ACETONIDE (PAGE 3-74)	200MG/ML	10	10/10/2018	FOR INJECTION
3	CREAM: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
4	FLUCONAZOLE ACETONIDE (PAGE 3-76)	100MG/ML	10	10/10/2018	FOR TOPICAL USE
5	SOLUTION: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
6	LIDEX	0.05%	10	10/10/2018	FOR TOPICAL USE
7	SYNTEX LABS/SYNTEX	0.05%	10	10/10/2018	FOR TOPICAL USE
8	FLUOXIMESTERONE (PAGE 3-77)	100MG/ML	10	10/10/2018	FOR TOPICAL USE
9	TABLET: ORAL	100MG/ML	10	10/10/2018	FOR ORAL USE
10	FLUOXIMESTERONE	100MG/ML	10	10/10/2018	FOR ORAL USE
11	BOLAR PHARMACEUTICAL	100MG/ML	10	10/10/2018	FOR ORAL USE
12	COLMED LABORATORIES	100MG/ML	10	10/10/2018	FOR ORAL USE
13	FOLIC ACID (PAGE 3-78)	100MG/ML	10	10/10/2018	FOR ORAL USE
14	TABLET: ORAL	100MG/ML	10	10/10/2018	FOR ORAL USE
15	VANGUARD LABS/VAH	100MG/ML	10	10/10/2018	FOR ORAL USE
16	FLUCONAZOLE INJECTION	200MG/ML	10	10/10/2018	FOR INJECTION
17	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
18	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
19	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
20	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
21	CREAM: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
22	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
23	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
24	SOLUTION: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
25	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
26	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
27	INJECTION: INJECTION	100MG/ML	10	10/10/2018	FOR INJECTION
28	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
29	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
30	CREAM: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
31	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
32	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
33	SOLUTION: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
34	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
35	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
36	INJECTION: INJECTION	100MG/ML	10	10/10/2018	FOR INJECTION
37	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
38	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
39	CREAM: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
40	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
41	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
42	SOLUTION: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
43	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
44	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
45	INJECTION: INJECTION	100MG/ML	10	10/10/2018	FOR INJECTION
46	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
47	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
48	CREAM: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
49	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
50	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
51	SOLUTION: TOPICAL	100MG/ML	10	10/10/2018	FOR TOPICAL USE
52	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE
53	PHARMAFAIR	100MG/ML	10	10/10/2018	FOR TOPICAL USE
54	INJECTION: INJECTION	100MG/ML	10	10/10/2018	FOR INJECTION
55	FLUCONAZOLE ACETONIDE	100MG/ML	10	10/10/2018	FOR TOPICAL USE

Original from
UNIVERSITY OF MICHIGAN

GENTAMICIN SULFATE (PAGE 3-79)

SOLUTION/DROPS; OPHTHALMIC

GENTACIDIN

AT COOPERVISION PHARMS EQ 3MG BASE/MLM

> ADD > GLIPIZIDE (PAGE 3-80)

> ADD > TABLET; ORAL

> ADD > GLUCOTROL

> ADD > ROERIG/PFIZER 5MGW

> ADD > 10MGW

> ADD > GLYBURIDE (PAGE 3-80)

> ADD > TABLET; ORAL

> ADD > DIABETA

> ADD > BX HOECHST-ROUSSEL 1.25MGW

> ADD > BX 2.5MGW

> ADD > BX 5MGW

> ADD > MICRONASE

> ADD > BX UPJOHN 1.25MGW

> ADD > BX 2.5MGW

> ADD > BX 5MGW

GONADOTROPIN, CHORIONIC (PAGE 3-81)

INJECTABLE; INJECTION

ANTUXITHIN S

/AP/ /PARKE-DAVIS/M-L/ /5.000 UNITS/VIAL/

GRISEOFULVIN, ULTRAMICROCRYSTALLINE (PAGE 3-82)

TABLET; ORAL

FULVICIN P/G 165

AB SCHERING 165MG

FULVICIN P/G 330

AB SCHERING 330MG

GRIS-PEG

> DLT > AB /DORSEY LABS/SANDOZ/ /165MG/

> DLT > AB /250MG/

> ADD > AB HERBERT LABS/ALLERGEN 125MG

> ADD > AB 250MG

GRISACTIN ULTRA

AB AYERST LABS/AMMO 165MGW

AB 330MGW

HEPARIN SODIUM (PAGE 3-83)

INJECTABLE; INJECTION

HEPARIN SODIUM

AP NATCON CHEMICAL 1,000 UNITS/MLM

HEPARIN SODIUM; SODIUM CHLORIDE - IN PLASTIC (PAGE 3-85)

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%

AP ABBOTT LABORATORIES 10,000 UNITS/100ML;450MG/100MLM

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%

AP ABBOTT LABORATORIES 10,000 UNITS/100ML;900MG/100MLM

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45%

AP ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100MLM

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

AP ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100MLM

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%

AP ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100MLM

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%

AP ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100MLM

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%

AP ABBOTT LABORATORIES 1,000 UNITS/100ML;900MG/100MLM

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%

AP ABBOTT LABORATORIES 100 UNITS/ML;45MG/MLM

HOMATROPINE METHYLBROMIDE (PAGE 3-86)

TABLET; ORAL

HOMATROP-10

/AA/ MISSION PHARMACAL 10MG

/AA/ /450-100'S/ /10MG/

/AA/ /1-11111/

HYDRALAZINE HYDROCHLORIDE (PAGE 3-86)

INJECTABLE; INJECTION

APRESOLINE

AP CIBA/CIBA-GEIGY 20MG/ML

HYDRALAZINE HCL

AP SOLOPAK LABORATORIES 20MG/MLM

TABLET; ORAL

HYDRALAZINE HCL

AA PAR PHARMACEUTICAL 100MGW

AA PUREPAC/KALIPHARMA 50MGW

> ADD > AA QUANTUM PHARMICS 10MGW

> ADD > AA 50MGW

> ADD > AA 100MGW

> ADD > AA 25MGW

> ADD > AA 50MGW

> ADD > AA 100MGW

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE (PAGE 3-87)

CAPSULE; ORAL

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25

AB ZENITH LABORATORIES 25MG;25MGW

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)

TABLET; ORAL
HYDROFLUMETHIAZIDE AND RESERPINE
BP COLMED LABORATORIES 50MG;0.125MG

HYDROMORPHONE HYDROCHLORIDE (PAGE 3-95)

INJECTABLE; INJECTION
DILAUDIO-HP
KNOLL PHARMACEUTICAL 10MG/ML

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL
HYDROXYZINE HCL
AB BARR LABORATORIES 10MG
AB DANBURY PHARMACAL 10MG
AB 25MG
AB 50MG

HYDROXYZINE PAMDATE (PAGE 3-96)

CAPSULE; ORAL
HYDROXYZINE PAMDATE
AB DURAMED PHARMS 50 25MG HCL
AB 50MG HCL
AB 100MG HCL
AB VANGARD LABS/WHI 25MG HCL
AB 50MG HCL

IBUPROFEN (PAGE 3-97)

TABLET; ORAL
IBUPROFEN
AB UPJOHN MANUFACTURING 600MG
AB RUFEN
AB BOOTS PHARMACEUTICAL 600MG

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
/BP/ /ANTIPRESS/ /25MG/
/BP/ /LEMON/ /25MG/
/AB/ /MAGATE/ /25MG/
/AB/ /AN ROBINS/ /25MG/
/AB/ /50MG/
IMIPRAMINE HCL
> ADD > AB GEIGY/CIBA-GEIGY 10MG
> ADD > AB 25MG
> ADD > AB 50MG

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
IMIPRAMINE HCL
AB PAR PHARMACEUTICAL 10MG
AB 25MG
AB 50MG
TOFRANEL
/BP/ /GEIGY/CIBA-GEIGY/ /25MG/
AB GEIGY/CIBA-GEIGY 25MG

INDOMETHACIN (PAGE 3-98)

CAPSULE; ORAL
INDOMETHACIN
AB MSD/MERCK 25MG
AB 50MG
> ADD > AB INDOMETHACIN
> ADD > AB LEDERLE LABS/AM CYAN 25MG
AB 50MG
AB MYLAN PHARMS 25MG
AB 50MG
> ADD > AB ZENITH LABORATORIES 25MG
> ADD > AB 50MG

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION
ISOETHARINE HCL
AN ARMOUR PHARM 0.1672%
AN 0.22%
AN 0.252%
AN INTL MEDICATION SYS 0.1672%
AN ROXANE LABORATORIES 0.1672%
AN TRAVENOL LABS 0.142%
AN 0.252%

ISONIAZID (PAGE 3-101)

SYRUP; ORAL
ISONIAZID
AB CAROLINA MED PRODS 50MG/5ML
AB EXHIFON
AB HOFFMANN-LA ROCHE 50MG/5ML

TABLET; ORAL
> DLT > /KALIFON/
> DLT > /AB/ /HOFFMANN-LA ROCHE/ /50MG/
> DLT > /AB/ /100MG/

Digitized by Google

METRONIDAZOLE (PAGE 3-122)

INJECTABLE; INJECTION
METRONIDAZOLE IN PLASTIC CONTAINER
 AP ABBOTT LABORATORIES 500MG/100MLX
METRO I.V. IN PLASTIC CONTAINER
 AP AM MCGAM/AM HOSP 500MG/100MLX

TABLET; ORAL
METRONIDAZOLE
 > ADD > AB CHELSEA LABORATORIES 500MGX
 AB LNK INTERNATIONAL 250MGX
 AB PAR PHARMACEUTICAL 250MGX
 AB 500MGX

MANDROLONE DECANOATE (PAGE 3-125)

INJECTABLE; INJECTION
MANDROLONE DECANOATE
 AQ CARTER-GLOGAU 200MG/MLX
 AQ LEMMON 100MG/ML
 50MG/ML
 AQ LYPHO-MED 100MG/MLX
 AQ 200MG/MLX
 AQ MAURRY BIOLOGICAL 100MG/MLX

NAPHAZOLINE HYDROCHLORIDE (PAGE 3-125)

SOLUTION/DROPS; OPHTHALMIC
VASOCON
 /AT/ /SAP/PA/COOPERVISION/ /0.12/
 AT COOPERVISION PHARMS 0.12

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-126)

> DLT > /solution/drops; ophthalmic/
 > DLT > /neo-hydrocortisol/
 > DLT > /NSAID/NEOMY/ /EQ 3.5MG BASE/ML EQ 0.5% PHOSPHATE/

NIACIN (PAGE 3-127)

TABLET; ORAL
NIACIN
 /AA/ /TULAN PHARMS/ /100MG/

NICOTINE RESIN COMPLEX (PAGE 3-127)

GUM, CHEWING; ORAL
 NICORETTE
 MERRELL DOM/DOM CHEN EQ 2MG BASEX

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION
NITRONAL
 AP G POHL-BOSKAMP 5MG/MLX
 1MG/MLX
NITROSTAT
 AP PARKE-DAVIS/M-L 5MG/MLX
TREDIL
 AM CRITICAL CARE/AHS 0.5MG/MLX

NYSTATIN (PAGE 3-129)

OINTMENT; TOPICAL
NYSTATIN
 AT CLAY-PARK LABS 100,000 UNITS/GX
 POWDER; ORAL
 NILSTAT
 LEDERLE LABS/AM CYAN 100GX
 TABLET; ORAL
NYSTATIN
 AA PAR PHARMACEUTICAL 500,000 UNITSX
 TABLET; VAGINAL
NYSTATIN
 AT E FOUGERA/BYK-GLDN 100,000 UNITSX
 AT PHARMADERM/BYK-GLDN 100,000 UNITSX
 AT QUANTUM PHARMICS 100,000 UNITSX

OXPRENOLOL HYDROCHLORIDE (PAGE 3-131)

CAPSULE; ORAL
 TRASICOR
 CIBA/CIBA-GEIGY 20MGX
 40MGX
 80MGX
 160MGX

OXTRIPHYLLINE (PAGE 3-131)

ELIXIR; ORAL
 OXTRIPHYLLINE
 BAY LABORATORIES 100MG/5MLX
 SYRUP; ORAL
OMOLEDTL
 AA PARKE-DAVIS/M-L 50MG/5ML
OXTRIPHYLLINE PEDIATRIC
 AA BAY LABORATORIES 50MG/5MLX

PREDNISOLONE TEBUTATE (PAGE 3-147)

INJECTABLE; INJECTION
HYDELTRA-TBA
BP MSD/MERCK 20MG/ML
BP PREDNISOLONE TEBUTATE
BP CARTER-GLOGAU LABS 20MG/ML

PREDNISONE (PAGE 3-147)

TABLET; ORAL
PREDNISONE
BX DURAMED PHARMS 5MG
BX 10MG
BX 20MG
/BX/ /MYLAN PHARMS/ /5MG/

PROBENECID (PAGE 3-149)

TABLET; ORAL
PROBENECID
> ADD > AB ZENITH LABORATORIES 500MG

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-149)

CAPSULE; ORAL
PROCAN
/AS/ PARKE-DAVIS/W-L /150MG/
/AS/ /300MG/

PROMETHAZINE HYDROCHLORIDE (PAGE 3-152)

SYRUP; ORAL
/PHENERGAN/
PHENERGAN PLAIN

PROPANTHELINE BROMIDE (PAGE 3-153)

TABLET; ORAL
PROPANTHELINE BROMIDE
AA PAR PHARMACEUTICAL 15MG

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-153)

CAPSULE; ORAL
PROPOXYPHENE HCL
AA RICHLYN LABORATORIES 65MG

PROPYLTHIOURACIL (PAGE 3-154)

TABLET; ORAL
PROPYLTHIOURACIL
/BP/ /MYLAN PHARMS/ /50MG/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-155)

SYRUP; ORAL
ACTAHIST
AA HR CENCI LABS 30MG/5ML; 1.25MG/5ML
HISTAFED
AA LIFE LABORATORIES 30MG/5ML; 1.25MG/5ML
/AA/ /PSEUDOEPHEDRINE/
/AA/ /BAY LABORATORIES/ /30MG/5ML; 1.25MG/5ML/
/AA/ /TRISOLIN/
/AA/ /NATI PHARM 'NFG/BARR/ /30MG/5ML; 1.25MG/5ML/
TRISOSED
AA HALSEY DRUG 30MG/5ML; 1.25MG/5ML

TABLET; ORAL
/TRISOLIN/
/AA/ /MO PHARMACEUTICAL/ /60MG; 2.5MG/
/AA/ /TRISOLIN/
/AA/ /PARSONS PHARMACEUTICAL/ /60MG; 2.5MG/
TRIPROLIDINE AND PSEUDOEPHEDRINE
AA BOLAR PHARMACEUTICAL 60MG; 2.5MG
/AA/ /WEST-WARD/ /60MG; 2.5MG/
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
AA CHELSEA LABORATORIES 60MG; 2.5MG

QUINIDINE GLUCONATE (PAGE 3-157)

TABLET, CONTROLLED RELEASE; ORAL
QUINIDINE GLUCONATE
AB ROXANE LABORATORIES 324MG

QUINIDINE SULFATE (PAGE 3-157)

TABLET; ORAL
QUINIDINE SULFATE
AB VITARINE/WEST CHEM 500MG

RAUMOLFIA SERPENTINA (PAGE 3-158)

TABLET; ORAL
RAUMOLFIA SERPENTINA
> DLT > /BP/ /KIRKMAN LABORATORIES/ /50MG/
> DLT > /BP/ /100MG/

SULFINPYRAZONE (PAGE 3-169)

CAPSULE; ORAL

SULFINPYRAZONE
 AB VANGARD LABS/194M 200MG#

SULFISOXAZOLE (PAGE 3-170)

SULFISOXAZOLE
 /C/ /VAGINAL/
 /GANTERIN/
 /AT/ /HOFFMAN-LA ROCHE/ /100/
 /AT/ /KORD-SULF/
 /AT/ /HOLLAND-RANTOS/ /100/

TABLET; ORAL

SULFISOXAZOLE
 /AB/ /RYLAN PHARMS/ /200MG/

TERBUTALINE SULFATE (PAGE 3-173)

TABLET; ORAL

TERBUTALINE SULFATE
 /BP/ /ASTRA PHARM PRODS/ /2.5MG/
 /BP/ /ASTRA PHARM PRODS/ /5MG/
 BP MERRELL DOW/DOW CHEM 2.5MG
 BP 5MG

TESTOSTERONE (PAGE 3-173)

INJECTABLE; INJECTION

TESTOSTERONE
 CARTER-GLOGAU LABS 50MG/ML#

TETRACYCLINE HYDROCHLORIDE (PAGE 3-174)

CAPSULE; ORAL

TETRACYCLINE HCL
 /AB/ /LEMON/ /250MG/

TABLET; ORAL

TETRACYCLINE HCL
 /AB/ /PAMMYCIN
 UPJOHN /250MG/
 /AB/ /SUNYCIN
 ER SQUIBB AND SONS 250MG

THALLOUS CHLORIDE, TL-201 (PAGE 3-175)

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201
 MEDI-PHYSICS 2MCI/ML

THEOPHYLLINE (PAGE 3-176)

(FOR CONTROLLED RELEASE PRODUCTS - SEE SPECIAL NOTE C.)

CAPSULE, CONTROLLED RELEASE; ORAL

THEOPHYLLINE
 BC FISON 100MG
 THEO-24
 BC SEARLE/SEARLE PHARMS 100MG#
 200MG#
 300MG#

ELIXIR; ORAL

THEOPHYLLINE
 AA HR CENCI LABS 80MG/15ML#

SOLUTION; ORAL

THEOPHYLLINE
 AA RIKER LABS/3M 80MG/15ML
THEOPHYLLINE
 AA ROXANE LABORATORIES 80MG/15ML#

TABLET, CONTROLLED RELEASE; ORAL

THEOPHYLLINE
 BC PURDUE FREDERICK 200MG#
 /400MG/
THEO-DUR
 BC KEY PHARMACEUTICALS 200MG
 UNIPHYL
 PURDUE FREDERICK 400MG

THIORIDAZINE HYDROCHLORIDE (PAGE 3-176)

CONCENTRATE; ORAL

THIORIDAZINE HCL
 AA CORD LABORATORIES 30MG/ML#
 AA 100MG/ML#
 AA NATL PHARM MFG/BARRE 100MG/ML#

TABLET; ORAL

THIORIDAZINE HCL
 AB SANDOZ PHARMS/SANDOZ 100MG
 AB 150MG
 AB 200MG
THIORIDAZINE HCL
 AB BARR LABORATORIES 10MG#
 AB 15MG#
 AB 25MG#
 AB 50MG#
 AB 100MG#
 AB 150MG#
 AB 200MG#
 AB 250MG#
 AB 300MG#
 AB 400MG#
 AB 500MG#
 AB 600MG#
 AB 800MG#
 AB 1000MG#

Original from
UNIVERSITY OF MICHIGAN

TYBAMATE (PAGE 3-186)

/CAPSULE; ORAL/
/TYBAMATE/
/H. ROBINSON/
/250MG/
/350MG/

VECURONIUM BROMIDE (PAGE 3-187)

INJECTABLE; INJECTION
NORCURON (NC-45)
ORGANON/AKZONA 10MG/VIALX

VERAPAMIL HYDROCHLORIDE (PAGE 3-187)

INJECTABLE; INJECTION
CALAM
AP SEARLE PHARMS 2.5MG/MLM
ISOPTIN
AP KNOLL PHARMACEUTICAL 2.5MG/ML

VITAMIN A PALMITATE (PAGE 3-188)

CAPSULE; ORAL
/SOLVITIN A/
/AA/ /TJONE, PAULSEN/ /Eq 50,000 UNITS BASE/

WATER FOR INJECTION, STERILE (PAGE 3-189)

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 100ZM
AP INVENEX LABS/DEXTER 100ZM

~~/AMINOPHYLLINE; PHENOBARBITAL; RACEPHEDRINE HYDROCHLORIDE/~~

ADDENDUM

Digitized by Google

/TRANLYCYPROME SULFATE/ (PAGE AD9)

/TABLET, ORAL/
/PAINKILLER/
/SKF LABORATORIES/ /EQ. LONG BASE/

/FERRISTYL / CYBA-CIBA-BEHR/
/DIMEPHINONE, MALEATE/

/EQUINATE, 30/ /MYTH LABS/AMH/
/NEPHROPHATE, PENTAEHYTHITOL, TETRAHYTATE/

/EQUINATE, 10/ /MYTH LABS/AMH/
/NEPHROPHATE, PENTAEHYTHITOL, TETRAHYTATE/

> DLT > /EQUINATE, 10/ /MYTH LABS/AMH/
> DLT > /ASPIRIN, ETHIOPEPTAZINE, CITRATE, NEPHROPHATE/

> DLT > /ZACTANE/ /MYTH LABS/AMH/
STANOCOL LABS/STERL

/ELEXIR DIMEAPP/ /AM ROBIN/

/BROMPHENIRAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE/

/BROMPHENIRAMINE MALEATE, PHENYLEPHRINE HYDROCHLORIDE/

/DIMEAPP /AM ROBIN/

/BROMPHENIRAMINE MALEATE, CODEINE, PHOSPHATE, GUAFENESIN/

/BROMPHENIRAMINE MALEATE, GUAFENESIN/

/BROMPHENIRAMINE MALEATE, GUAFENESIN/

/CARTIN BA/ /MCNEIL PHARM/

> DLT > /CARTAX-20/ /ROEBIG/PEIZER/

> DLT > /CARTAX-10/ /ROEBIG/PEIZER/

> DLT > /CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

/CARTAX-10/ /ROEBIG/PEIZER/

CURRENT STATUS - INEFFECTIVE

/ACTIFED-2, EXPECTORANT/ /BUBBLEBAGS, WELLCOME/

/CODEINE PHOSPHATE, GUAFENESIN/

/PSEUDOPHEDRINE, HYDROCHLORIDE, TRIPROLOLIDINE, HYDROCHLORIDE/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

/AMPHYL, EXPECTORANT/ /MASTON, LABORATORIES/

DESIGNATING LIST - OTHER THAN "EXEMPT" (COURT ORDER) CATEGORY

CUMULATIVE SUPPLEMENT NUMBER 9 / AUGUST '63 - MAY '64

